Drug Profile
Research programme: autoimmune disease therapeutics - Janssen Biotech/Nodality
Latest Information Update: 28 Jul 2018
Price :
$50
*
At a glance
- Originator Janssen Biotech; Nodality
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Inflammatory bowel diseases; Rheumatoid arthritis
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for research development in Inflammatory-bowel-disease in USA
- 28 Jul 2018 No recent reports of development identified for research development in Rheumatoid-arthritis in USA
- 08 Jan 2014 Early research in Inflammatory bowel disease in USA (unspecified route)